NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Cantor Fitzgerald Pounding Table on NeuroPace Inc (NPCE): 'we would be buyers of NPCE on today's pullback'
May 27, 2025 1:05 PM EDTCantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $16.00 price target on NeuroPace Inc (NASDAQ: NPCE).
The analyst comments "Investment Summary. Today (5/27), Overweight-rated NeuroPace (NPCE) announced preliminary one-year results from its NAUTILUS study evaluating the RNS System in patients with idiopathic generalized epilepsy (IGE). While the study did not meet its primary effectiveness endpoint in the overall... More
